← Leaderboards
Evette S Radisky
National Jewish Health
$7,854,444
Attributed
$9,711,321
Total exposure
14
Grants
12
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.7M · FY2007–25$2M$1.5M$1M$500K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,711,321 · 14
By mechanism
R01$8,443,967 · 5
R21$1,157,267 · 3
F32$86,388 · 1
P41$23,699 · 5
Top collaborators
- Gregory Paul Downey4 shared
- Derek C Radisky4 shared
Most similar at National Jewish Health
Same institution · by research overlap
- Willi K Born$4,873,117
- James R Hagman$10,069,394
- Elizabeth Frances Redente$4,940,326
Others in their field
Top investigators on “Affinity”
- Dennis R. Burton · Scripps Research Institute$64,397,776
- James E Crowe · Vanderbilt University Medical Center$53,471,415
- David M. Margolis · University Of Texas Sw Med Ctr/Dallas$45,445,140
- Timothy A Springer · Boston Children'S Hospital$41,593,445
- Misty Ward Stevens · Intervexion Therapeutics, Llc$38,187,594
- Rafi Ahmed · Emory University$36,776,987
Research focus
AffinityMalignant NeoplasmsProteinsStructureMediatingEnzymesPeptide HydrolasesTissuesTherapeutic TargetInsightMolecularBaseDesignPublishingPlayDirected Molecular EvolutionBindingSpecificityPharmaceutical PreparationsProtease InhibitorInhibitor/AntagonistMethodologyComplexMouse Model
Grant awards (35)
Proteolysis in the Pathogenesis of ARDS$683,217
R01 · FY2025 · HL
Engineering tissue inhibitor of metalloproteinases-2 (TIMP-2) for triple negative breast cancer therapy$322,492
R01 · FY2025 · CA · contact PI
Exploiting new approaches for selective inhibition of trypsins$293,116
R01 · FY2025 · GM · contact PI
Proteolysis in the Pathogenesis of ARDS$677,606
R01 · FY2024 · HL
Engineering tissue inhibitor of metalloproteinases-2 (TIMP-2) for triple negative breast cancer therapy$306,368
R01 · FY2024 · CA · contact PI
Exploiting new approaches for selective inhibition of trypsins$290,781
R01 · FY2024 · GM · contact PI
Proteolysis in the Pathogenesis of ARDS$696,074
R01 · FY2023 · HL
Engineering tissue inhibitor of metalloproteinases-2 (TIMP-2) for triple negative breast cancer therapy$316,042
R01 · FY2023 · CA · contact PI
Engineering selective inhibition of metalloproteinases by tissue inhibitors of metalloproteinases (R01 GM132100 RESUB - *TIMPs)$313,000
R01 · FY2023 · GM · contact PI
Exploiting new approaches for selective inhibition of trypsins$293,784
R01 · FY2023 · GM · contact PI
Proteolysis in the Pathogenesis of ARDS$728,418
R01 · FY2022 · HL
Engineering tissue inhibitor of metalloproteinases-2 (TIMP-2) for triple negative breast cancer therapy$316,042
R01 · FY2022 · CA · contact PI
Engineering selective inhibition of metalloproteinases by tissue inhibitors of metalloproteinases (R01 GM132100 RESUB - *TIMPs)$313,000
R01 · FY2022 · GM · contact PI
Exploiting new approaches for selective inhibition of trypsins$301,404
R01 · FY2022 · GM · contact PI
Engineering tissue inhibitor of metalloproteinases-2 (TIMP-2) for triple negative breast cancer therapy$336,617
R01 · FY2021 · CA · contact PI
Engineering selective inhibition of metalloproteinases by tissue inhibitors of metalloproteinases (R01 GM132100 RESUB - *TIMPs)$313,000
R01 · FY2021 · GM · contact PI
Engineering selective inhibition of metalloproteinases by tissue inhibitors of metalloproteinases (R01 GM132100 RESUB - *TIMPs)$313,000
R01 · FY2020 · GM · contact PI
Targeting the IL-6 - SPINK1 regulatory axis in ovarian clear cell carcinoma$214,456
R21 · FY2019 · CA · contact PI
Targeting the IL-6 - SPINK1 regulatory axis in ovarian clear cell carcinoma$183,322
R21 · FY2018 · CA · contact PI
Inhibiting serine protease-induced prostate cancer progression$325,287
R01 · FY2017 · CA · contact PI
Targeting MMP-9 for breast cancer therapy (R21 CA205471 Resubmission)$204,447
R21 · FY2017 · CA · contact PI
Inhibiting serine protease-induced prostate cancer progression$325,287
R01 · FY2016 · CA · contact PI
Targeting MMP-9 for breast cancer therapy (R21 CA205471 Resubmission)$170,408
R21 · FY2016 · CA · contact PI
Inhibiting serine protease-induced prostate cancer progression$324,875
R01 · FY2015 · CA · contact PI
Inhibiting serine protease-induced prostate cancer progression$316,213
R01 · FY2014 · CA · contact PI
Defining SPINK1 as a tumor driver and therapeutic target in ovarian cancer$165,673
R21 · FY2014 · CA · contact PI
Inhibiting serine protease-induced prostate cancer progression$338,344
R01 · FY2013 · CA · contact PI
Defining SPINK1 as a tumor driver and therapeutic target in ovarian cancer$218,961
R21 · FY2013 · CA · contact PI
HUMAN MESOTRYPSIN S195A - COMPLEX WITH APPI - CRYSTAL SCREEN CONDITION #33$3,058
P41 · FY2011 · RR · contact PI
HUMAN CATIONIC TRYPSIN S195A/R117H - COMPLEX WITH BPTI - CRYSTAL SCREEN CONDITIO$2,930
P41 · FY2010 · RR · contact PI
HUMAN MESOTRYPSIN S195A - COMPLEX WITH APPI - CRYSTAL SCREEN CONDITION #33$2,433
P41 · FY2010 · RR · contact PI
HUMAN CATIONIC TRYPSIN S195A/R117H - COMPLEX WITH BPTI$8,536
P41 · FY2008 · RR · contact PI
HUMAN CATIONIC TRYPSIN S195A/R117H - COMPLEX WITH BPTI$6,742
P41 · FY2007 · RR · contact PI
Structural Investigations of Productive Enzyme Complexes$46,192
F32 · FY2002 · GM
Structural Investigations of Productive Enzyme Complexes$40,196
F32 · FY2001 · GM